HemoGenyx Pharmaceuticals

Receive alerts
Market Cap:
£9.39 m
52 weeks high
52 weeks low

Viewing results 1-25 of 29


Hemogenyx Pharmaceuticals PLC advisory board member recognised for breast cancer breakthrough

H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been acknowledged with the 2019 Lasker-DeBakey Clinical Medical Research Award...

1 week, 3 days ago

Hemogenyx files new patent application for CDX technology

The application covers the antibody's use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia...

on 12/7/19

Hemogenyx develops new mouse model which could play a big role in future wars

Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war...

on 24/6/19

Hemogenyx reports encouraging data for bone marrow transplant therapy

"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”...

on 12/6/19

Hemogenyx soars as CDX antibody demonstrates effectiveness against acute myeloid leukemia

Vladislav Sandler, the company’s chief executive, said the firm was “encouraged” by the results...

on 5/6/19

Hemogenyx Pharmaceuticals delivers encouraging data on antibody drug candidate

“This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor," said CEO Vladislav Sandler...

on 30/5/19

Hemogenyx says progress continuing towards Investigational New Drug submission for CDX antibody

The AIM-listed group last year signed an agreement with a global bio-pharmaceutical company to develop its CDX antibodies under a potential for licensing deal...

on 30/4/19

Hemogenyx Pharmaceuticals chief to present at immunotherapy conference

The address will highlight the fact that despite numerous advances in understanding AML, treatment remains “unsatisfactory”...

on 31/1/19

Hemogenyx Pharma resetting the bar in blood cancers

"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland...

on 29/1/19

Hemogenyx set for talks over potential licensing deal with global pharma later this month

Hemogenyx is already working with the unnamed company to further develop its CDX antibodies and it hopes to open talks over a possible licensing deal in the coming weeks...

on 8/1/19

Hemogenyx Pharmaceuticals unveils new senior appointment

Andrew Wright, meanwhile, is coming in as financial controller and company secretary...

on 5/11/18

Orgenesis to invest at least another US$1mln into Hemogenyx as part of latest collaboration deal

This time around, the investment is centred on Hemogenyx’s Hu-PHEC technology - a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient...

on 23/10/18

Hemogenyx to receive US$1mln investment from Orgenesis as part of new collaboration deal

The biopharmas will work together to develop Hemogenyx’s AHC technology, while Orgenesis will invest at least US$1mln in Hemogenyx through a convertible loan...

on 19/10/18

Hemogenyx teams up with Johnson & Johnson to develop new lupus treatment

Hemogenyx is to build a humanised mouse model of the lupus disease, which scientists will then use to help develop a new treatment...

on 15/10/18

HemoGenyx optimistic on CDX antibodies prospects

HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX antibodies during the first half...

on 28/9/18

Hemogenyx Pharmaceuticals chief hails a year of significant progress

Boss, Dr Vladislav Sandler, said the company is making progress towards submitting an investigational new drug application ...

on 31/5/18

Hemogenyx teams up with global pharma company to help further develop CDX antibodies

Hemogenyx will now have access to free technical support and advanced methods of engineering which should aid development of its flagship CDX antibodies...

on 14/5/18

HemoGenyx signs collaboration agreement with Rockefeller University to develop new Lupus treatments

Vladislav Sandler, CEO and co-founder of HemoGenyx, said: “This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding”...

on 8/5/18

Hemogenyx appoints Marc Feldmann, pioneer of anti-TNF therapy for rheumatoid arthritis, as its new executive chairman

The biotechnology group said Feldmann has a “unique blend of scientific, medical and commercial experience and expertise”...

on 3/4/18

Hemogenyx shares leap as it signs collaboration deal with major US biotechnology company

The biotech firm said the application of Hemogenyx's humanised mice as a tool for drug development and testing forms the basis of its collaboration with the US company...

on 13/3/18

HemoGenyx shares soar after news of first solid data on leukemia treatment

The company said first data results have shown that its lead product, CDX bi-specific antibodies, is capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro...

on 27/2/18